Genfit SA GNFTF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if GNFTF is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $2.98
- Day Range
- $2.95–2.95
- 52-Week Range
- $2.95–4.39
- Bid/Ask
- $0.01 / $495,603.97
- Market Cap
- $147.09 Mil
- Volume/Avg
- 150 / 744
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 4.74
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 159
- Website
- https://www.genfit.com
Comparables
Valuation
|
Metric
|
GNFTF
|
AELIS
|
AB
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 1.22 |
Price/Book Value | 1.96 | 9.98 | — |
Price/Sales | 4.74 | 13.79 | 153.65 |
Price/Cash Flow | — | — | — |
Price/Earnings
GNFTF
AELIS
AB
Financial Strength
|
Metric
|
GNFTF
|
AELIS
|
AB
|
|---|---|---|---|
Quick Ratio | 2.87 | 2.29 | 1.39 |
Current Ratio | 2.94 | 2.41 | 1.43 |
Interest Coverage | −5.54 | −38.47 | −6.34 |
Quick Ratio
GNFTF
AELIS
AB
Profitability
|
Metric
|
GNFTF
|
AELIS
|
AB
|
|---|---|---|---|
Return on Assets (Normalized) | −15.01% | −13.75% | −62.36% |
Return on Equity (Normalized) | −36.95% | −26.44% | — |
Return on Invested Capital (Normalized) | −17.70% | −31.64% | — |
Return on Assets
GNFTF
AELIS
AB
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Zlztqcbt | Skqk | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Dnrldydwd | Gqcmdb | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Lvykrvkvg | Zbvsy | $97.8 Bil | |
MRNA
| Moderna Inc | Yhxhvldwd | Wbj | $38.8 Bil | |
ARGX
| argenx SE ADR | Tphbqwzj | Drh | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Lfftxyxrh | Hvyk | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Cvxjqkql | Bzghw | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Wdgsmvb | Gbjrmd | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Bwzjwlpkwn | Xxjspw | $12.5 Bil | |
INCY
| Incyte Corp | Vjtrsfkp | Vghsf | $11.5 Bil |